192 related articles for article (PubMed ID: 21638324)
1. A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.
Gallagher CL; Christian BT; Holden JE; Dejesus OT; Nickles RJ; Buyan-Dent L; Bendlin BB; Harding SJ; Stone CK; Mueller B; Johnson SC
Mov Disord; 2011 Sep; 26(11):2032-8. PubMed ID: 21638324
[TBL] [Abstract][Full Text] [Related]
2. A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]-fluoro-L-dopa uptake in Parkinson's disease.
Li CT; Palotti M; Holden JE; Oh J; Okonkwo O; Christian BT; Bendlin BB; Buyan-Dent L; Harding SJ; Stone CK; DeJesus OT; Nickles RJ; Gallagher CL
Synapse; 2014 Aug; 68(8):325-31. PubMed ID: 24710997
[TBL] [Abstract][Full Text] [Related]
3. Comparative assessment of 6-[
Becker G; Bahri MA; Michel A; Hustadt F; Garraux G; Luxen A; Lemaire C; Plenevaux A
J Neurochem; 2017 May; 141(4):626-635. PubMed ID: 28294334
[TBL] [Abstract][Full Text] [Related]
4. Subregional 6-[18F]fluoro-ʟ-m-tyrosine uptake in the striatum in Parkinson's disease.
Asari S; Fujimoto K; Miyauchi A; Sato T; Nakano I; Muramatsu S
BMC Neurol; 2011 Mar; 11():35. PubMed ID: 21429212
[TBL] [Abstract][Full Text] [Related]
5. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study.
Brück A; Aalto S; Nurmi E; Vahlberg T; Bergman J; Rinne JO
Mov Disord; 2006 Jul; 21(7):958-63. PubMed ID: 16550545
[TBL] [Abstract][Full Text] [Related]
6. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
[TBL] [Abstract][Full Text] [Related]
7.
Li W; Lao-Kaim NP; Roussakis AA; Martín-Bastida A; Valle-Guzman N; Paul G; Loane C; Widner H; Politis M; Foltynie T; Barker RA; Piccini P
Mov Disord; 2018 Jan; 33(1):117-127. PubMed ID: 29082547
[TBL] [Abstract][Full Text] [Related]
8. Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6-[(18)F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects.
Rousset OG; Deep P; Kuwabara H; Evans AC; Gjedde AH; Cumming P
Synapse; 2000 Aug; 37(2):81-9. PubMed ID: 10881028
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine.
Doudet DJ; Chan GL; Jivan S; DeJesus OT; McGeer EG; English C; Ruth TJ; Holden JE
J Cereb Blood Flow Metab; 1999 Mar; 19(3):278-87. PubMed ID: 10078880
[TBL] [Abstract][Full Text] [Related]
10. A probe for intracerebral aromatic amino-acid decarboxylase activity: distribution and kinetics of [18F]6-fluoro-L-m-tyrosine in the human brain.
Nahmias C; Wahl L; Chirakal R; Firnau G; Garnett ES
Mov Disord; 1995 May; 10(3):298-304. PubMed ID: 7651447
[TBL] [Abstract][Full Text] [Related]
11. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Morrish PK; Rakshi JS; Bailey DL; Sawle GV; Brooks DJ
J Neurol Neurosurg Psychiatry; 1998 Mar; 64(3):314-9. PubMed ID: 9527140
[TBL] [Abstract][Full Text] [Related]
12. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data.
Sawle GV; Playford ED; Burn DJ; Cunningham VJ; Brooks DJ
Arch Neurol; 1994 Mar; 51(3):237-43. PubMed ID: 8129633
[TBL] [Abstract][Full Text] [Related]
13. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease.
Ceravolo R; Piccini P; Bailey DL; Jorga KM; Bryson H; Brooks DJ
Synapse; 2002 Mar; 43(3):201-7. PubMed ID: 11793426
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
Kanazawa M; Ohba H; Harada N; Kakiuchi T; Muramatsu S; Tsukada H
J Nucl Med; 2016 Feb; 57(2):303-8. PubMed ID: 26564319
[TBL] [Abstract][Full Text] [Related]
15. Modeling of fluorine-18-6-fluoro-L-Dopa in humans.
Wahl L; Nahmias C
J Nucl Med; 1996 Mar; 37(3):432-7. PubMed ID: 8772639
[TBL] [Abstract][Full Text] [Related]
16. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
Cumming P; Gjedde A
Synapse; 1998 May; 29(1):37-61. PubMed ID: 9552174
[TBL] [Abstract][Full Text] [Related]
17. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study.
Rakshi JS; Uema T; Ito K; Bailey DL; Morrish PK; Ashburner J; Dagher A; Jenkins IH; Friston KJ; Brooks DJ
Brain; 1999 Sep; 122 ( Pt 9)():1637-50. PubMed ID: 10468504
[TBL] [Abstract][Full Text] [Related]
18. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
Brooks DJ; Ibanez V; Sawle GV; Quinn N; Lees AJ; Mathias CJ; Bannister R; Marsden CD; Frackowiak RS
Ann Neurol; 1990 Oct; 28(4):547-55. PubMed ID: 2132742
[TBL] [Abstract][Full Text] [Related]
19. 6-[18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods.
Hoshi H; Kuwabara H; Léger G; Cumming P; Guttman M; Gjedde A
J Cereb Blood Flow Metab; 1993 Jan; 13(1):57-69. PubMed ID: 8417011
[TBL] [Abstract][Full Text] [Related]
20. Comparison of striatal 18F-dopa uptake in adult-onset dystonia-parkinsonism, Parkinson's disease, and dopa-responsive dystonia.
Turjanski N; Bhatia K; Burn DJ; Sawle GV; Marsden CD; Brooks DJ
Neurology; 1993 Aug; 43(8):1563-8. PubMed ID: 8351012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
